Genetic Analysis AS announced ththat GA has entered a distribution and technology transfer agreement with Omnigene Medical Technologies Ltd. In the first stage of the collaboration, Omnigene will launch the GA-map® Dysbiosis Test, a CE-marked standardized gut microbiome test as a service to the UEA market. Gut microbiome profiling is increasingly required in the field of precision medicine as a surrogate endpoint or exploratory biomarker in research. This is due both to the impact of the gut microbiome on health and pharmaceuticals that can affect the microbiota composition itself.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.64 NOK | -4.48% | +18.52% | -24.71% |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-24.71% | 2.44M | |
-17.89% | 8.25B | |
+39.20% | 3.57B | |
-39.11% | 2.46B | |
-8.06% | 2.46B | |
-7.35% | 2.38B | |
-12.61% | 1.81B | |
-19.01% | 1.55B | |
-40.66% | 1.21B | |
+7.56% | 1.11B |
- Stock Market
- Equities
- GEAN Stock
- News Genetic Analysis
- Genetic Analysis AS and Omnigene Medical Technologies Ltd. Enter a Distribution Agreement to Launch GA-mA-map